WEST PALM BEACH, Fla., Jan. 7, 2015 (GLOBE NEWSWIRE) -- Glucose Health, Inc. ("GLUC" or the "Company") today announced it has completed implementation of Food and Drug Administration (FDA) Current Good Manufacturing Practices (CGMP). The Dietary Supplement (DS) CGMP rule in 21 CFR part 111 of the FDA's regulations requires companies which manufacture, package, label, or hold a dietary supplement to establish and follow current good manufacturing practice to ensure the quality of the dietary supplement and to ensure that the dietary supplement is packaged and labeled as specified in the master manufacturing record.
Glucose Health™ branded products are targeted to proactive consumers interested in natural blood sugar maintenance. In addition to direct-to-consumer sales, Glucose Health™ branded products are also targeted for channel sales to national pharmacy retailers. National pharmacy retailers require evidence of regulatory compliance including with (DS) CGMP prior to new products being placed on their store shelves for purchase by consumers.
Glucose Health, Inc. retained Marc Sanchez (www.fdaatty.com), an attorney specializing in FDA and United States Department of Agriculture (USDA) regulatory compliance, to advise the Company with the implementation.
About Glucose Health, Inc. (OTCQB:GLUC)
Glucose Health™ branded products uniquely engage the large and growing market of proactive consumers interested in achieving natural blood sugar maintenance. The Centers for Disease Control and Prevention (CDC) now estimates 2 in 5 adults - 40% of Americans - will develop Type 2 diabetes at some point in their lifetime. Glucose Health™ branded products are marketed to consumers at Glucose Health, Inc.'s product website www.glucosehealth.com and to pharmacy and natural health retailers nationwide.
For more information and a complimentary investor package, please contact Glucose Health, Inc. investor relations at 1-888-987-6315 (press 1).